PE20090241A1 - Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12 - Google Patents
Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12Info
- Publication number
- PE20090241A1 PE20090241A1 PE2008000685A PE2008000685A PE20090241A1 PE 20090241 A1 PE20090241 A1 PE 20090241A1 PE 2008000685 A PE2008000685 A PE 2008000685A PE 2008000685 A PE2008000685 A PE 2008000685A PE 20090241 A1 PE20090241 A1 PE 20090241A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- quinoline
- alkenyl
- covalent link
- heterocyclyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- ZEXKKIXCRDTKBF-UHFFFAOYSA-N quinoline-2-carboxamide Chemical class C1=CC=CC2=NC(C(=O)N)=CC=C21 ZEXKKIXCRDTKBF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A DERIVADOS DE QUINOLINA-CARBOXAMIDA DE FORMULA (I) DONDE E ES UN HETEROCICLICO DE 3 A 10 MIEMBROS; X ES N O C-R8; Q ES UN ENLACE COVALENTE, ALQUENILO(C2-C10), ALQUINILO(C2-C10), ENTRE OTROS; J ES H, ALQUILO(C1-C6), ALQUILEN(C0-C4)-O-CH2-FLUOROALQUILEN(C1-C3)-CH2-O-ALQUILO(C1-C4), ENTRE OTROS; Z ES ALQUILENO(C0-C8), ALQUENILO(C2-C10), ALQUINILO(C2-C10), ENTRE OTROS; A ES UN ENLACE COVALENTE, ALQUILENO(C3-C8), CICLOALQUILENO(C3-C8) O HETEROCICLILO(C3-C15); B ES UN ENLACE COVALENTE, ALQUENILO(C2-C10), ALQUINILO(C2-C10), ENTRE OTROS; V ES HETEROCICLILO O N(R1)-HETEROCICLILO(C3-C15); G ES UN ENLACE COVALENTE, ALQUENILO(C2-C10), ALQUINILO(C2-C10), ENTRE OTROS; M ES H, ALQUILO(C1-C8), CICLOALQUILO(C3-C8), ENTRE OTROS; R1 ES H, ALQUILO(C1-C4), ENTRE OTROS; R2, R3, R4, R5, R6 Y R8 SON CADA UNO H, ALQUILO(C1-C6), HALOGENO, CN, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DEL ACIDO 4-[(S)-4-CARBOXI-2-({4-[2-(4-HIDROXI-2-METOXICARBONIL-PIRROLIDIN-1-IL)-2-OXO-ETOXI]-7-METIL-QUINOLINA-2-CARBONIL}-AMINO)-BUTIRIL]-PIPERAZINA-1-CARBOXILICO, ESTER ETILICO DEL ACIDO 4-[(S)-4-CARBOXI-2-({7-METIL-4-[2-OXO-2-(2-OXO-PIRROLIDIN-1-IL)-ETOXI]-QUINOLINA-2-CARBONIL}-AMINO)-BUTIRIL]-PIPERAZINA-1-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ADENOSINA 5'-DIFOSFATO (ADP) DE PLAQUETAS P2Y12 SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES TROMBOEMBOLICAS O RESTENOSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07008209 | 2007-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090241A1 true PE20090241A1 (es) | 2009-04-03 |
Family
ID=38462433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000685A PE20090241A1 (es) | 2007-04-23 | 2008-04-21 | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8669266B2 (es) |
| EP (1) | EP2148871A1 (es) |
| JP (1) | JP5309131B2 (es) |
| KR (1) | KR20100015886A (es) |
| CN (1) | CN101663293B (es) |
| AR (1) | AR066225A1 (es) |
| AU (1) | AU2008241091B2 (es) |
| BR (1) | BRPI0810462A2 (es) |
| CA (1) | CA2684644A1 (es) |
| CL (1) | CL2008001157A1 (es) |
| IL (1) | IL201620A (es) |
| MX (1) | MX2009011089A (es) |
| MY (1) | MY153427A (es) |
| PA (1) | PA8777901A1 (es) |
| PE (1) | PE20090241A1 (es) |
| TW (1) | TW200848042A (es) |
| UY (1) | UY31039A1 (es) |
| WO (1) | WO2008128647A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8840927B2 (en) | 2001-02-28 | 2014-09-23 | Covalon Technologies Inc. | Method of making anti-microbial polymeric surfaces |
| US8288371B2 (en) | 2007-10-05 | 2012-10-16 | Pharmacopeia, Llc | Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation |
| WO2009069100A1 (en) | 2007-11-29 | 2009-06-04 | Actelion Pharmaceuticals Ltd | Phosphonic acid derivates and their use as p2y12 receptor antagonists |
| AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
| RU2401831C2 (ru) * | 2008-12-15 | 2010-10-20 | Алла Хем, Ллс | Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения |
| JP5536873B2 (ja) * | 2009-04-08 | 2014-07-02 | アクテリオン ファーマシューティカルズ リミテッド | ６−（３−アザ−ビシクロ［３．１．０］ヘクス−３−イル）−２−フェニル−ピリミジン（６−（３−ａｚａ−ｂｉｃｙｃｌｏ［３．１．０］ｈｅｘ−３−ｙｌ）−２−ｐｈｅｎｙｌ−ｐｙｒｉｍｉｄｉｎｅｓ） |
| US8664203B2 (en) | 2009-04-22 | 2014-03-04 | Actelion Pharmaceuticals Ltd. | Thiazole derivatives and their use as P2Y12 receptor antagonists |
| US8729095B2 (en) | 2009-08-28 | 2014-05-20 | Daiichi Sankyo Company, Limited | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases |
| AR079451A1 (es) * | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
| CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| CN102584852B (zh) * | 2011-12-30 | 2014-08-13 | 厦门大学 | 真菌代谢产物桥南霉素及其制备方法和应用 |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| EP2725025A1 (fr) * | 2012-10-26 | 2014-04-30 | Sanofi | Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12 |
| RU2662810C2 (ru) | 2013-02-21 | 2018-07-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Хиназолины в качестве ингибиторов киназы |
| CN104109158A (zh) * | 2013-04-16 | 2014-10-22 | 上海医药工业研究院 | 一种纯化利伐沙班的方法 |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| DE102015217396B4 (de) | 2014-09-11 | 2018-07-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | System, insbesondere System zur Eingabesteuerung für eine Arbeitshilfe |
| CN106496249B (zh) * | 2015-09-07 | 2019-12-13 | 江苏恒瑞医药股份有限公司 | 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用 |
| CN109689649B (zh) * | 2016-07-14 | 2022-07-19 | 百时美施贵宝公司 | 经二环杂芳基取代的化合物 |
| TWI752086B (zh) | 2016-09-22 | 2022-01-11 | 瑞士商愛杜西亞製藥有限公司 | 結晶型式 |
| TWI765002B (zh) | 2017-03-15 | 2022-05-21 | 瑞士商愛杜西亞製藥有限公司 | 受體拮抗劑之皮下投藥 |
| CN107648607A (zh) * | 2017-09-11 | 2018-02-02 | 南昌大学 | 嘌呤2y12受体拮抗剂在制备糖尿病神经病理损伤疾病药物中的应用 |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| WO2023108363A1 (en) * | 2021-12-13 | 2023-06-22 | Beijing Honghui Meditech Co., Ltd | Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition |
| CN115429874A (zh) * | 2022-09-20 | 2022-12-06 | 暨南大学 | 水蛭素靶向并抑制dpp4治疗糖尿病 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| DK1094816T3 (da) | 1998-07-06 | 2009-04-06 | Bristol Myers Squibb Co | Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| CN102617567A (zh) | 2001-09-21 | 2012-08-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
| RS20050450A (sr) * | 2002-12-11 | 2007-08-03 | Schering Aktiengesellschaft, | 2-aminokarbonil-hinolin jedinjenja kao antagonisti adenozin difosfat receptora krvne pločice |
| CN100471842C (zh) | 2003-07-24 | 2009-03-25 | 安斯泰来制药有限公司 | 喹诺酮衍生物或其盐 |
| US7157445B2 (en) * | 2004-02-26 | 2007-01-02 | Aventis Pharma S.A. | Administration of enoxaparin sodium to patients with severe renal impairment |
| JP2008094720A (ja) | 2005-01-20 | 2008-04-24 | Astellas Pharma Inc | キノロン誘導体のプロドラッグ又はその塩 |
| TW200640877A (en) * | 2005-04-28 | 2006-12-01 | Actelion Pharmaceuticals Ltd | Pyrimidine derivatives |
| CN101287727A (zh) * | 2005-08-17 | 2008-10-15 | 先灵公司 | 新的高亲和力喹啉基激酶配体 |
-
2008
- 2008-04-09 CN CN200880013208XA patent/CN101663293B/zh not_active Expired - Fee Related
- 2008-04-09 EP EP08735104A patent/EP2148871A1/en not_active Withdrawn
- 2008-04-09 MX MX2009011089A patent/MX2009011089A/es active IP Right Grant
- 2008-04-09 CA CA002684644A patent/CA2684644A1/en not_active Abandoned
- 2008-04-09 JP JP2010504490A patent/JP5309131B2/ja not_active Expired - Fee Related
- 2008-04-09 BR BRPI0810462-0A2A patent/BRPI0810462A2/pt not_active IP Right Cessation
- 2008-04-09 WO PCT/EP2008/002790 patent/WO2008128647A1/en not_active Ceased
- 2008-04-09 AU AU2008241091A patent/AU2008241091B2/en not_active Ceased
- 2008-04-09 KR KR1020097022288A patent/KR20100015886A/ko not_active Ceased
- 2008-04-09 MY MYPI20094191A patent/MY153427A/en unknown
- 2008-04-21 AR ARP080101660A patent/AR066225A1/es not_active Application Discontinuation
- 2008-04-21 TW TW097114392A patent/TW200848042A/zh unknown
- 2008-04-21 PE PE2008000685A patent/PE20090241A1/es not_active Application Discontinuation
- 2008-04-21 UY UY31039A patent/UY31039A1/es not_active Application Discontinuation
- 2008-04-22 CL CL2008001157A patent/CL2008001157A1/es unknown
- 2008-04-23 PA PA20088777901A patent/PA8777901A1/es unknown
-
2009
- 2009-10-05 US US12/573,551 patent/US8669266B2/en not_active Expired - Fee Related
- 2009-10-19 IL IL201620A patent/IL201620A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001157A1 (es) | 2008-11-03 |
| IL201620A (en) | 2013-11-28 |
| AR066225A1 (es) | 2009-08-05 |
| CA2684644A1 (en) | 2008-10-30 |
| JP2010524984A (ja) | 2010-07-22 |
| BRPI0810462A2 (pt) | 2014-10-14 |
| CN101663293B (zh) | 2013-07-31 |
| MX2009011089A (es) | 2009-10-30 |
| US8669266B2 (en) | 2014-03-11 |
| WO2008128647A1 (en) | 2008-10-30 |
| TW200848042A (en) | 2008-12-16 |
| UY31039A1 (es) | 2008-11-28 |
| HK1141803A1 (en) | 2010-11-19 |
| US20100135999A1 (en) | 2010-06-03 |
| KR20100015886A (ko) | 2010-02-12 |
| MY153427A (en) | 2015-02-13 |
| JP5309131B2 (ja) | 2013-10-09 |
| AU2008241091A1 (en) | 2008-10-30 |
| AU2008241091B2 (en) | 2013-05-09 |
| CN101663293A (zh) | 2010-03-03 |
| PA8777901A1 (es) | 2008-11-19 |
| EP2148871A1 (en) | 2010-02-03 |
| IL201620A0 (en) | 2010-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090241A1 (es) | Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12 | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20080361A1 (es) | Compuestos derivados de purina como activadores del receptor de adenosina a2a | |
| PE20080405A1 (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb | |
| PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20080890A1 (es) | DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES | |
| PE20070848A1 (es) | Derivados de pirimidina como ligandos del receptor de histamina h4 | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| PE20110924A1 (es) | Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
| PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
| PE20061442A1 (es) | Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia | |
| PE20080211A1 (es) | Compuestos derivados de 6-(bencilo sustituido con heterociclilo)-4-oxoquinolina como inhibidores de integrasa del vih | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
| PE20041016A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| PE20090183A1 (es) | Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5 | |
| PE20090679A1 (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
| PE20141005A1 (es) | 1,3-oxazinas como inhibidores de bace1 y/o bace2 | |
| PE20090546A1 (es) | Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5 | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20040189A1 (es) | Pirimidina y piridina biciclicos como inhibidores de p38 quinasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |